FDA Approves Aduhelm, First Targeted Alzheimer’s Therapy
In a significant decision, the FDA approved Adulhelm (aducanumab) as a first targeted Alzheimer's treatment, and first new therapy since 2003.
0 Comments
FDA Approves Aduhelm, First Targeted Alzheimer’s Therapy
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed